Background
==========

With advances in endovascular techniques, endovascular coil embolization of intracranial aneurysms is considered a valid alternative to surgical clipping \[[@b1-medscimonit-23-5697],[@b2-medscimonit-23-5697]\]. However, the treatment of wide-necked aneurysms is still a challenge because of the risk of coils protrusion from the aneurysm into the parent artery. Several endovascular techniques have been described to treat wide-necked aneurysms, including balloon-assisted coil placement and double microcatheter technique. The use of balloon-assisted coil placement or double microcatheter technique can sometimes be limited, owing to the lack of permanent support for the coil mass inside the aneurysm sac. Stent-assisted technology has been developed to obtain a safe coil packing into the sac in these aneurysms.

Some scholars have demonstrated stent-assisted technology for the treatment of aneurysms facilitates a higher coil packing density and a more stable aneurysm neck sealing \[[@b3-medscimonit-23-5697]--[@b7-medscimonit-23-5697]\]. Some operators are reluctant to use this technique because sequent antiplatelet therapy after stenting may increase the risk of rebleeding and recurrence \[[@b8-medscimonit-23-5697]\]. A number of investigators have compared the results of stent-assisted coiling (SAC) and non-stent-assisted coiling (non-SAC) for intracranial aneurysms \[[@b6-medscimonit-23-5697],[@b9-medscimonit-23-5697],[@b10-medscimonit-23-5697]\]. Only a few studies have compared the efficacy and safety of SAC and non-SAC for ruptured intracranial aneurysms \[[@b6-medscimonit-23-5697],[@b10-medscimonit-23-5697]\]. In the present study, we conducted a retrospective single-center analysis on the clinical and angiographic outcomes of the ruptured aneurysms that were embolized with SAC or non-SAC.

Material and Methods
====================

Patient characteristics
-----------------------

The study was approved by the local Institutional Review Board and Ethics Committee. We retrospectively reviewed data of patients with ruptured intracranial aneurysms who underwent coil embolization between July 2004 and June 2015 in our institution. Inclusion criteria for this study were ruptured aneurysms treated no more than 28 days after the initial rupture \[[@b11-medscimonit-23-5697]\]. The exclusion criteria included dissecting, infectious, or traumatic aneurysms, blood blister-like aneurysms, patients presenting with large (\>50 mL) intraparenchymal hematomas, staged stent placement, and those who were treated by sole stenting.

A total of 279 ruptured aneurysms (279 patients) were treated with endovascular embolization. The study consisted of 101 males (36.2%) and 178 females (63.8%), with a median age of 56.0 years (range, 16--82 years). The baseline data on age, sex, medical history, aneurysm size, location, and Hunt and Hess grade were recorded.

Pharmacologic therapy protocol and endovascular procedures
----------------------------------------------------------

For wide-neck aneurysms (neck \>4 mm and/or dome/neck ratio ≤2), a stent-assisted technique (Enterprise stent, Codman Neurovascular; Neuroform stent, Boston Scientific; Solitaire stent, ev3) was required. Pharmacologic therapy protocol was based on the literatures \[[@b11-medscimonit-23-5697],[@b12-medscimonit-23-5697]\]. Patients were pre-medicated with 100 mg aspirin and a loading dose of 75 mg clopidogrel for two to three days before stent-assisted embolization (92 patients). For the stent used without premedication, 300 mg clopidogrel and 300 mg aspirin was administered via a naso/orogastric tube (21 patients).

All of the coil embolization surgeries were performed under general anesthesia. A bolus of 3,000 IU of heparin was administered after femoral arterial sheath placement and intermittent boluses of 1,000 IU per hour were subsequently administered. Coils used in the study were platinum coils. The antiplatelet regimen after SAC was 100 mg daily and clopidogrel 75 mg daily for six weeks, followed by a 100 mg dose of aspirin daily, for an indefinite length of time.

Two different stent placement strategies were used in this series: a) "coil through" technique, which means that the stent was first fully deployed across the aneurysm neck and then the aneurysm was catheterized by navigating through the tines of the stent; and b) "jailing" technique, which means that some or part of the coils were introduced into the aneurysm sac before implanting the stent.

Occlusion status initially and at follow-up was classified as complete (100%), near complete (90% to 99%), or incomplete (\<90%). Angiographic results were assessed by two experienced neuro-interventionists (YL and FW) independently. Disagreements were resolved by consensus.

Follow-up data
--------------

During the follow-up period, angiographic evaluation with digital subtraction angiography (DSA) was performed at three to six months after endovascular treatment. If no recanalization evidence was observed, the subsequent angiographic evaluation was performed at 18 months after treatment. Changes in angiographic outcomes were classified as follows: stable occlusion (no change in coil configuration, obliteration grade, or contrast filling), further occlusion (progressive occlusion or involution of the neck remnant or contrast filling in aneurysm), and recanalization (aneurysm recurrence evident due to neck growth, coil compaction, coil extrusion by aneurysm degradation, or new sac formation).

Clinically, the neurological and functional status was evaluated according to the modified Rankin scale (mRS). Good outcomes were defined as a mRS score of 0--2; poor outcomes were defined as a mRS score of 3--6.

Statistical analyses
--------------------

SPSS 19.0 software (SPSS Inc., Chicago, IL, USA) was used for statistical analyses. A Mann-Whitney U test was performed for non-normally distributed continuous variables. A Pearson χ^2^ or Fisher's exact test was used to compare proportions. The univariate analysis cutoff for inclusion in the logistic regression analysis was *p*\<0.20. The level of statistical significance was set at 0.05.

Results
=======

The patient characteristics and the aneurysm features are summarized in [Table 1](#t1-medscimonit-23-5697){ref-type="table"}. The two groups were similar in all baseline characteristics.

Stents used in treatment
------------------------

Among 279 aneurysms, 113 aneurysms were treated with SAC. SAC was performed with the Enterprise stent in 10 aneurysms, the Solitaire stent in 63 aneurysms, and the Neuroform stent in 40 aneurysms.

Adverse events and mortality
----------------------------

Adverse events are summarized in [Table 1](#t1-medscimonit-23-5697){ref-type="table"}. Ischemic complications were seen in 14 patients (5.0%). Cumulative adverse events occurred in 28 patients (10.0%). Adverse events occurred in similar proportions of patients in the two groups (11.5% in the SAC group and 9.0% in the non-SAC group). The incidence of permanent disabling neurologic deficit was also similar in the two groups (7.1% and 5.4% in the SAC and non-SAC respectively).

Follow-up outcomes
------------------

Clinical follow-up data were available in 207 patients (74.2%) ([Table 2](#t2-medscimonit-23-5697){ref-type="table"}). During a median follow-up period of 28 months (range, 3--124 months), two cases of rebleeding occurred (non-SAC group). The rate of good outcomes was 91.8% (190/207). Statistical analysis demonstrated that clinical outcomes were correlated with adverse events (*p*=0.043, odds ratio=4.59), large aneurysms (*p*=0.013, odds ratio=10.24), and Hunt and Hess grade (*p*=0.001, odds ratio=13.51).

Angiographic follow-up was available in 106 aneurysms (38.0%) with a median follow-up period of 7.5 months (range, 3--114 months) ([Table 3](#t3-medscimonit-23-5697){ref-type="table"}). Follow-up angiograms showed complete occlusion in 61 aneurysms (57.5%), and near complete or incomplete occlusion in 45 aneurysms (42.5%).

Changes in angiographic outcomes at follow-up after coiling embolization are summarized in [Table 3](#t3-medscimonit-23-5697){ref-type="table"}. Statistical analysis demonstrated that stent placement might enhance progressive occlusion and reduced the rate of aneurysm recanalization (*p*\<0.001).

Aneurysm-occlusion status at follow-up were correlated with stent placement (*p*\<0.001, odds ratio=5.85) and initial aneurysm-occlusion status (*p*=0.027, odds ratio=3.78) ([Table 4](#t4-medscimonit-23-5697){ref-type="table"}).

Initial and follow-up angiographic outcomes are summarized in [Table 5](#t5-medscimonit-23-5697){ref-type="table"}. In the SAC group, complete occlusion at follow-up was seen in 100% (11/11) of the initial complete occlusion group compared with 67.4% (29/43) of the initial near complete or incomplete occlusion group (*p*=0.048 in the Fisher's exact test). The incidence of complete occlusion at follow-up was 67.4% in the initial near completely or incompletely occluded aneurysms with SAC compared with 35.9% in the initial near completely occluded aneurysms with non-SAC (*p*=0.004 in the χ^2^ test). The incidence of complete occlusion at follow-up was (100%) in the initial completely occluded aneurysms with SAC compared with 35.9% in the initial near completely or incompletely occluded aneurysms with non-SAC (*p*\<0.001 in the Fisher's exact test). The incidence of complete occlusion at follow-up was higher in the initial completely occluded aneurysms with SAC (100%) than in the initial completely occluded aneurysms with non-SAC (53.8%) (*p*=0.016 in the Fisher's exact test).

Discussion
==========

The introduction of stent-assisted coiling (SAC) has led to a conceptual shift in the management of intracranial aneurysm. Nonetheless, stent assistance requires antiplatelet agents to prevent in-stent thrombosis, which may increase the risk of subarachnoid hemorrhage and recanalization of aneurysm. The use of a stent during the acute post-hemorrhage period is controversial because of concerns about the efficacy and risk of dual antiplatelet therapy.

In this study, we noted a comparable complication rate (11.5%) in the SAC group with previously studies. Yang et al. reported a complication rate of 14.2% in a single-center series of 211 consecutive cases \[[@b11-medscimonit-23-5697]\]. Bodily et al. reported a hemorrhagic complication rate of 8% and an ischemic complication rate of 6% in a systematic review \[[@b13-medscimonit-23-5697]\]. The complication rate (9.0%) in our non-SAC group was in line with previous results in the management of acutely ruptured aneurysms, which have ranged from 8.7% to 18.9% \[[@b6-medscimonit-23-5697],[@b10-medscimonit-23-5697],[@b14-medscimonit-23-5697]\].

There have been conflicting results regarding the safety of SAC in the management of intracranial aneurysms. Some scholars demonstrated that SAC was associated with a higher rate of complication than non-SAC \[[@b10-medscimonit-23-5697],[@b13-medscimonit-23-5697]\]. Whereas other scholars demonstrated SAC was associated with a comparable rate of complication than non-SAC \[[@b6-medscimonit-23-5697],[@b7-medscimonit-23-5697],[@b9-medscimonit-23-5697]\].

SAC might be associated with a higher rate of ischemic events because of the thrombogenicity of stents. In our study, the ischemic complication rate was 7.1% in the SAC group compared with 3.6% in the non-SAC group (*p*=0.193). This finding suggests dual antiplatelet therapy prevents ischemic events for ruptured aneurysms with SAC. The intraoperative rupture rate was 2.7% in the SAC group compared with 4.2% in the non-SAC group (*p*=0.745). SAC for ruptured aneurysm, as compared with non-SAC, was not associated with an increased incidence of adverse events, morbidity, or mortality. Our study confirmed the previous findings that SAC was associated with reasonable complication rates for ruptured aneurysms \[[@b6-medscimonit-23-5697]\].

Whether stenting might cause poor clinical outcomes in patients with ruptured aneurysms is less clear. Bodily et al. noted that SAC in ruptured aneurysms was associated with worse clinical outcomes compared with data for non-SAC \[[@b13-medscimonit-23-5697]\]. However, some scholars demonstrated SAC was associated with a comparable rate of clinical outcomes than non-SAC \[[@b6-medscimonit-23-5697],[@b15-medscimonit-23-5697]\]. In our study, clinical outcomes at follow-up was correlated with adverse events (*p*=0.043, odds ratio=4.59), large aneurysms (*p*=0.013, odds ratio=10.24), and Hunt and Hess grade (*p*=0.001, odds ratio=13.51)). SAC for ruptured aneurysm, as compared with non-SAC, was not associated with an increased incidence of poor clinical outcomes at follow-up.

Theoretically, stent deployment provides a mechanical scaffold for coils inside an aneurysm, allowing for increased packing density. In previous clinical studies, there have been conflicting results regarding the efficacy between SAC and non-SAC. Some scholars demonstrated SAC facilitated a higher coil packing density and a more stable aneurysm neck sealing \[[@b3-medscimonit-23-5697]--[@b7-medscimonit-23-5697],[@b16-medscimonit-23-5697]\]. However, Hwang et al. noted that stent placement provided no better long-term angiographic outcomes for aneurysms, with an unfavorable configuration for coiling \[[@b17-medscimonit-23-5697]\]. In our study, complete obliteration rate was 25.7% (29/113) in SAC, and was 31.3% (52/166) in non-SAC. A possible explanation is that the flexibility of a microcatheter tip is decreased following stent deployment, and thus, may result in looser aneurysm packing \[[@b9-medscimonit-23-5697]\].

Embolized aneurysms can develop a worse degree of closure even when the initial occlusion is complete \[[@b18-medscimonit-23-5697]\]. Choi et al. reported a series of 91 completely coiled aneurysms, with the recanalization rate of 26.4% \[[@b19-medscimonit-23-5697]\]. Xavier et al. reported a series of 83 completely coiled aneurysms, with the recanalization rate of 24% \[[@b20-medscimonit-23-5697]\]. In our study, the recanalization rate was 7.4% in the SAC group and was 32.7% in the non-SAC group. In addition, the occlusion rate was 59.3% in the SAC group and 17.3% in the non-SAC group. The *p* value was significant (*p*\<0.001). These findings suggest SAC can provide durable closure for ruptured aneurysms, as shown in [Tables 3](#t3-medscimonit-23-5697){ref-type="table"} and [4](#t4-medscimonit-23-5697){ref-type="table"}.

In the condition of SAC, complete occlusion at follow-up was seen in 100% (11/11) of the initial complete occlusion group compared with 67.4% (29/43) of the initial near complete or incomplete occlusion group (*p*=0.048). The incidence of complete occlusion at follow-up was higher in the initial completely occluded aneurysms with SAC (100%) than in the initial completely occluded aneurysms with non-SAC (53.8%) (*p*=0.016). These findings suggest that complete occlusion should be achievable with SAC as it seems sufficient to provide durable closure for ruptured aneurysms.

Limitations
-----------

This was a retrospective study in a single center, which may limit the generalization of our findings. In addition, some patients did not undergo long-term follow-up. Only 106 out of 279 aneurysms were available for angiographic follow-up, which may have introduced bias. Further study with a larger number of patients and adequate follow-up would be necessary to validate our findings. In addition, exclusion of other type of aneurysms may restrict the ability to generalize our results to ruptured aneurysms in general.

Conclusions
===========

Compared with coil placement alone, SAC may have better durability, with comparable safety for ruptured intracranial aneurysms. Complete occlusion should be achievable with SAC as it seems sufficient to provide durable closure for ruptured aneurysms.

**Source of support:** Departmental sources

SAC

:   stent-assisted coiling

non-SAC

:   non-stent-assisted coiling

mRS

:   modified Rankin scale

DSA

:   digital subtraction angiography

###### 

Comparison of stent-assisted coiling (SAC) and non-stent-assisted coiling (non-SAC).

                                                                                                  SAC (n=113)                                                  non-SAC (n=166)                                               *p* Value
  ----------------------------------------------------------------------------------------------- ------------------------------------------------------------ ------------------------------------------------------------- -------------------------------------------------------------
  Characteristics                                                                                                                                                                                                            
   Female                                                                                         79 (69.9)                                                    99 (59.6)                                                     0.080[\*](#tfn2-medscimonit-23-5697){ref-type="table-fn"}
   Hypertension                                                                                   59 (52.2)                                                    70 (42.2)                                                     0.099[\*](#tfn2-medscimonit-23-5697){ref-type="table-fn"}
   Hunt and Hess grade                                                                                                                                                                                                       0.544[\*](#tfn2-medscimonit-23-5697){ref-type="table-fn"}
   I--II                                                                                          60 (53.1)                                                    82 (49.4)                                                     
   III--IV                                                                                        53 (46.9)                                                    84 (50.6)                                                     
   Median age (y)                                                                                 57.0                                                         56.0                                                          0.133[\#\#](#tfn3-medscimonit-23-5697){ref-type="table-fn"}
  Size                                                                                                                                                                                                                       0.100[\*](#tfn2-medscimonit-23-5697){ref-type="table-fn"}
   Tiny (\<3 mm)                                                                                  28 (24.8)                                                    24 (14.5)                                                     
   Small (3--10 mm)                                                                               80 (70.8)                                                    130 (78.3)                                                    
   Large (11--25 mm)                                                                              5 (4.4)                                                      11 (6.6)                                                      
   Giant (\>25 mm)                                                                                0 (0)                                                        1 (0.6)                                                       
  Location                                                                                                                                                                                                                   0.234[\*](#tfn2-medscimonit-23-5697){ref-type="table-fn"}
   Anterior circulation                                                                           101 (89.4)                                                   155 (93.4)                                                    
   Posterior circulation                                                                          12 (10.6)                                                    11 (6.6)                                                      
  Occlusion status                                                                                                                                                                                                           0.194[\*](#tfn2-medscimonit-23-5697){ref-type="table-fn"}
   Complete                                                                                       29 (25.7)                                                    52 (31.3)                                                     
   Near complete                                                                                  69 (61.0)                                                    102 (61.5)                                                    
   Incomplete                                                                                     15 (13.3)                                                    12 (7.2)                                                      
  Adverse events                                                                                                                                                                                                             
   Ischemic events                                                                                8 (7.1)                                                      6 (3.6)                                                       0.193[\*](#tfn2-medscimonit-23-5697){ref-type="table-fn"}
   Intraoperative rupture                                                                         3 (2.7)                                                      7 (4.2)                                                       0.745[\*](#tfn2-medscimonit-23-5697){ref-type="table-fn"}
   Other adverse events                                                                           2 (1.8)[§](#tfn4-medscimonit-23-5697){ref-type="table-fn"}   2 (1.4)[\#](#tfn5-medscimonit-23-5697){ref-type="table-fn"}   1.000[\*](#tfn2-medscimonit-23-5697){ref-type="table-fn"}
   Permanent disabling neurologic deficit[\*\*](#tfn6-medscimonit-23-5697){ref-type="table-fn"}   8 (7.1)                                                      9 (5.4)                                                       0.570[\*](#tfn2-medscimonit-23-5697){ref-type="table-fn"}
   Periprocedural mortality                                                                       2 (1.8)                                                      9 (5.4)                                                       0.209[\*](#tfn2-medscimonit-23-5697){ref-type="table-fn"}

Unless indicated otherwise, data are number of cases, with percentages in parentheses.

χ^2^ test or Fisher's exact test;

Mann-Whitney U test;

One case of coil migration, and one case of rebleeding;

One case of gastrointestinal bleeding, and one case of coil stretching;

Because of treatment-related complications, complications of SAH, or unfavorable evolution of SAH.

###### 

Potential risk factors related to follow-up results.

                                      Good outcome(n=190)   Poor outcome(n=17)   p value                                                       Logistic regression p value
  ----------------------------------- --------------------- -------------------- ------------------------------------------------------------- --------------------------------------------------------------------------------------
  Median age (y)                      56.0                  56.0                 0.338[\*](#tfn8-medscimonit-23-5697){ref-type="table-fn"}     
  Sex                                                                            0.673[\#\#](#tfn9-medscimonit-23-5697){ref-type="table-fn"}   
   Women                              113 (91.1)            11 (8.9)                                                                           
   Men                                77 (92.8)             6 (7.2)                                                                            
  Hunt and Hess grade                                                            0.001[\#\#](#tfn9-medscimonit-23-5697){ref-type="table-fn"}   
   1--3                               181 (96.8)            6 (3.2)                                                                            
   4                                  9 (45.0)              11 (55.0)                                                                          0.001 (13.51) \[3.05--59.9\][\*\*](#tfn10-medscimonit-23-5697){ref-type="table-fn"}
  Size                                                                           0.066[\#\#](#tfn9-medscimonit-23-5697){ref-type="table-fn"}   
   Tiny (\<3 mm)                      37 (86.0)             6 (14.0)                                                                           
   Small (3--10 mm)                   145 (94.2)            9 (5.8)                                                                            
   Large (11--25 mm)                  8 (80.0)              2 (20.0)                                                                           0.013 (10.24) \[1.62--64.68\][\*\*](#tfn10-medscimonit-23-5697){ref-type="table-fn"}
  Location                                                                       0.031[\#\#](#tfn9-medscimonit-23-5697){ref-type="table-fn"}   
   Anterior circulation               178 (93.2)            13 (6.8)                                                                           
   Posterior circulation              12 (75.0)             4 (25.0)                                                                           
  Stent placement                                                                0.832[\#\#](#tfn9-medscimonit-23-5697){ref-type="table-fn"}   
   Yes                                87 (91.6)             8 (8.4)                                                                            
   No                                 109 (92.4)            9 (7.6)                                                                            
  Initial aneurysm-occlusion status                                              0.573[\#\#](#tfn9-medscimonit-23-5697){ref-type="table-fn"}   
   Complete occlusion                 52 (89.7)             6 (10.3)                                                                           
   Near or incomplete occlusion       138 (92.6)            11 (7.4)                                                                           
  Adverse Events                                                                 0.009[\#\#](#tfn9-medscimonit-23-5697){ref-type="table-fn"}   
   Yes                                13 (72.2)             5 (27.8)                                                                           0.043 (4.59) \[1.05--20.12\][\*\*](#tfn10-medscimonit-23-5697){ref-type="table-fn"}
   No                                 177 (93.7)            12 (6.3)                                                                           

Unless indicated otherwise, data are number of cases, with percentages in parentheses.

Mann-Whitney U test;

χ^2^ test or Fisher's exact test;

Numbers in parentheses are the odds ratio.

Numbers in brackets are the 95% confidence interval. *p* values were obtained with binary logistic regression.

###### 

Angiographic outcome and angiographic changes at follow-up after stent-assisted coiling and non-stent-assisted coiling embolization.

                                  SAC (n=54)   non-SAC (n=52)   *p* Value
  ------------------------------- ------------ ---------------- -----------
  Angiographic outcome                                          \<0.001
   Complete occlusion             40 (74.1)    21 (40.4)        
   Near or incomplete occlusion   14 (25.9)    31 (59.6)        
  Angiographic changes                                          \<0.001
   Recanalization                 4 (7.4)      17 (32.7)        
   Stable                         18 (33.3)    26 (50.0)        
   Further occlusion              32 (59.3)    9 (17.3)         

###### 

Predictors of aneurysm obliteration at last follow-up.

                                           Aneurysm-occlusion status at follow-up   *p* Value   Logistic regression *p* value                                    
  ---------------------------------------- ---------------------------------------- ----------- ---------------------------------------------------------------- ---------------------------------------------------------------------------------------
  Median age (y)                           55.0                                     54.0        0.658[\*](#tfn13-medscimonit-23-5697){ref-type="table-fn"}       
  Stent placement                                                                               \<0.001[\#\#](#tfn14-medscimonit-23-5697){ref-type="table-fn"}   
   Yes                                     40 (74.1)                                14 (25.9)                                                                    \<0.001 (5.85) \[2.30--14.91\][\*\*](#tfn15-medscimonit-23-5697){ref-type="table-fn"}
   No                                      21 (40.4)                                31 (59.6)                                                                    
  Size                                                                                          0.144[\#\#](#tfn14-medscimonit-23-5697){ref-type="table-fn"}     
   Tiny                                    12 (63.2)                                7 (36.8)                                                                     
   Small                                   48 (59.3)                                33 (40.7)                                                                    
   Large or giant                          1 (16.7)                                 5 (83.3)                                                                     
  Initial aneurysm-occlusion status                                                             0.049[\#\#](#tfn14-medscimonit-23-5697){ref-type="table-fn"}     
   Complete occlusion                      18 (75.0)                                6 (25.0)                                                                     0.027 (3.78) \[1.16--12.27\][\*\*](#tfn15-medscimonit-23-5697){ref-type="table-fn"}
   Near complete or incomplete occlusion   43 (52.4)                                39 (47.6)                                                                    
  Location                                                                                      0.696                                                            
   Anterior circulation                    56 (56.6)                                43 (43.4)                                                                    
   Posterior circulation                   5 (71.4)                                 2 (28.6)                                                                     

Unless indicated otherwise, data are number of cases, with percentages in parentheses.

Mann-Whitney U test;

χ^2^ test or Fisher's exact test;

Numbers in parentheses are the odds ratio.

Numbers in brackets are the 95% confidence interval. *p* Values were obtained with binary logistic regression.

###### 

Initial and follow-up angiographic outcomes of aneurysms treated with coil embolization.

  Initial status                                    Aneurysm-occlusion status at follow-up   
  ------------------------------------------------- ---------------------------------------- -----------
  Complete occlusion with non-SAC (n=13)            7 (53.8)                                 6 (46.2)
  Near complete or incomplete with non-SAC (n=39)   14 (35.9)                                25 (64.1)
  Complete occlusion with SAC (n=11)                11 (100)                                 0 (0)
  Near complete or incomplete with SAC (n=43)       29 (67.4)                                14 (32.6)

Unless indicated otherwise, data are number of cases, with percentages in parentheses.
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